Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT01708603 |
Date of registration:
|
12/09/2012 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
AMAGINE-2 |
Scientific title:
|
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2 |
Date of first enrolment:
|
August 2012 |
Target sample size:
|
1831 |
Recruitment status: |
Terminated |
URL:
|
https://clinicaltrials.gov/show/NCT01708603 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Australia
|
Austria
|
Canada
|
Czech Republic
|
Czechia
|
France
|
Hungary
|
Netherlands
|
Poland
|
Portugal
|
Spain
|
United States
| | | | |
Contacts
|
Name:
|
MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Amgen |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Subject has had stable moderate to severe plaque psoriasis for at least 6 months
- Subject has involved body surface area (BSA) = 10%, PASI = 12, and sPGA = 3 at
screening and at baseline
Exclusion Criteria:
- Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,
medication-induced psoriasis, or other skin conditions at (eg, eczema) that would
interfere with study evaluations
- Subject has known history of Crohn's disease
- Subject has any other significant concurrent medical condition or laboratory
abnormalities, as defined in the study protocol
- Subject has not stopped using certain psoriasis therapies as defined in the study
protocol
- Subject has previously used ustekinumab or any anti-IL-17 biologic therapy
- Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in
the study
- Female subject is unwilling to use highly effective methods of birth control unless 2
years post-menopausal or surgically sterile
Age minimum:
18 Years
Age maximum:
75 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Moderate to Severe Plaque Psoriasis
|
Intervention(s)
|
Drug: 140 mg brodalumab
|
Drug: ustekinumab
|
Drug: placebo
|
Drug: 210 mg brodalumab
|
Primary Outcome(s)
|
Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12
[Time Frame: 12 weeks]
|
Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12
[Time Frame: 12 weeks]
|
Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12
[Time Frame: 12 Weeks]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
|